ÂÜŔňÂŇÂ×

Christopher Leo is a founding member of Back Bay Life Science Advisors. His focus areas include business unit, product and market strategy development and due diligence support for clients ranging from emerging biotech through specialty pharma and large biopharma/medtech/tools companies.

Dr. Leo has extensive experience across markets and therapeutic areas, focusing on rare diseases, women’s health, neurology, and autoimmune diseases. He also has significant expertise at the interface of the industry and the academic community around strategies for collaborating and advancing novel technology.

Dr. Leo joined Back Bay Life Science Advisors from Genzyme, where he led strategic & competitive planning projects for the company’s rare genetic disease and biosurgery business units. Before Genzyme, he was a Director with Leerink Swann’s Strategic Advisory group and a Principal in Wood Mackenzie’s Life Science consulting practice. Before transitioning to strategy consulting, Dr. Leo was Director of the Belfer Cancer Genomics Center at the Dana Farber Cancer Institute, under the leadership of Drs. Ron DePinho and Lynda Chin.

Dr. Leo completed his doctorate in Biochemistry and Molecular Pharmacology at the University of Massachusetts Medical School and holds an undergraduate degree in Biology, cum laude, from The College of the Holy Cross.